The Role of Surgery for Oligometastatic Non-Small Cell Lung Cancer

被引:7
作者
Euhus, Caleb J. [1 ]
Ripley, Taylor R. [1 ]
Medina, Cristian G. [1 ]
机构
[1] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Thorac Surg, 1 Moursund St, Houston, TX 77030 USA
关键词
oligometastatic non-small cell lung cancer; metastatic non-small cell lung cancer; NSCLC history; lung cancer staging; surgery and NSCLC; local consolidative therapy (LCT); locally-aggressive therapy (LAT); LONG-TERM SURVIVAL; PROGNOSTIC-FACTORS; THERAPY; RADIOTHERAPY; CLASSIFICATION; MULTICENTER; PROGRESSION; METASTASIS; MANAGEMENT; RESECTION;
D O I
10.3390/cancers14102524
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This article clarifies the context and definition of the term oligometastasis as it applies to non-small cell lung cancer and reviews the current results in the use of surgery for its management. Ideally after reading this article, practitioners will be better equipped to pick patients for locally aggressive therapy, and researchers will be primed to design the next generation of studies that prioritize treatments in the management of this historically deadly disease. Oligometastatic non-small cell lung cancer (NSCLC) is metastatic disease that refers to a limited number of metastatic sites. It is analogous to an intermediate stage of NSCLC, between localized and widely metastatic disease, even though no staging criteria establishes this distinction. Oligometastatic NSCLC describes a patient subgroup with limited metastasis to one or a few organs. These patients seem to have a more indolent cancer than those with diffuse metastasis. For these select patients with oligometastatic disease, the use of palliative systemic therapy over local aggressive treatment may be a missed opportunity to improve survival. The clear definition of this subgroup and identification of the best treatment remains the current challenge in the management of the disease. Surgery was the early cornerstone in the treatment of limited disease; however, as modalities such as chemotherapy, stereotactic radiosurgery, and immunotherapy have matured, the role of excision is less clearly defined. There are sparse randomized controlled trials comparing the efficacy of different treatment modalities in patients with oligometastatic NSCLC. However, there is a growing body of retrospective research detailing the prognostic factors that characterize the role of surgery in the management of these patients. This article clarifies the context and definition of the term oligometastatic, as it applies to NSCLC, and reviews the current results in the use of surgery for its management.
引用
收藏
页数:9
相关论文
共 28 条
  • [1] An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer
    Ashworth, Allison B.
    Senan, Suresh
    Palma, David A.
    Riquet, Marc
    Ahn, Yong Chan
    Ricardi, Umberto
    Congedo, Maria T.
    Gomez, Daniel R.
    Wright, Gavin M.
    Melloni, Giulio
    Milano, Michael T.
    Sole, Claudio V.
    De Pas, Tommaso M.
    Carter, Dennis L.
    Warner, Andrew J.
    Rodrigues, George B.
    [J]. CLINICAL LUNG CANCER, 2014, 15 (05) : 346 - 355
  • [2] Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage
    Collaud, Stephane
    Stahel, Rolf
    Inci, Ilhan
    Hillinger, Sven
    Schneiter, Didier
    Kestenholz, Peter
    Weder, Walter
    [J]. LUNG CANCER, 2012, 78 (03) : 234 - 238
  • [3] Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
    Counago, Felipe
    Luna, Javier
    Leonardo Guerrero, Luis
    Vaquero, Blanca
    Cecilia Guillen-Sacoto, Maria
    Gonzalez-Merino, Teresa
    Taboada, Begona
    Diaz, Veronica
    Rubio-Viqueira, Belen
    Aurora Diaz-Gavela, Ana
    Jose Marcos, Francisco
    del Cerro, Elia
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (10): : 318 - 339
  • [4] Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
    De Ruysscher, Dirk
    Wanders, Rinus
    Hendriks, Lizza E.
    van Baardwijk, Angela
    Reymen, Bart
    Houben, Ruud
    Bootsma, Gerben
    Pitz, Cordula
    van Eijsden, Linda
    Dingemans, Anne-Marie C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1958 - 1961
  • [5] Radical Treatment of Non-Small-Cell Lung Cancer Patients with Synchronous Oligometastases Long-Term Results of a Prospective Phase II Trial (Nct01282450)
    De Ruysscher, Dirk
    Wanders, Rinus
    van Baardwijk, Angela
    Dingemans, Anne-Marie C.
    Reymen, Bart
    Houben, Ruud
    Bootsma, Gerben
    Pitz, Cordula
    van Eijsden, Linda
    Geraedts, Wiel
    Baumert, Brigitta G.
    Lambin, Philippe
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1547 - 1555
  • [6] Commentary: Keeping surgery relevant in oligometastatic non-small cell lung cancer
    Donington, Jessica S.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 157 (04) : 1629 - 1630
  • [7] The IASLC Lung Cancer Staging Project Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
    Eberhardt, Wilfried E. E.
    Mitchell, Alan
    Crowley, John
    Kondo, Haruhiko
    Kim, Young Tae
    Turrisi, Andrew, III
    Goldstraw, Peter
    Rami-Porta, Ramon
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) : 1515 - 1522
  • [8] The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
    Goldstraw, Peter
    Chansky, Kari
    Crowley, John
    Rami-Porta, Ramon
    Asamura, Hisao
    Eberhardt, Wilfried E. E.
    Nicholson, Andrew G.
    Groome, Patti
    Mitchell, Alan
    Bolejack, Vanessa
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : 39 - 51
  • [9] Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
    Gomez, Daniel R.
    Tang, Chad
    Zhang, Jianjun
    Blumenschein, George R., Jr.
    Hernandez, Mike
    Lee, J. Jack
    Ye, Rong
    Palma, David A.
    Louie, Alexander, V
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Welsh, James W.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tsao, Anne S.
    Sepesi, Boris
    Swisher, Stephen G.
    Heymach, John, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18) : 1558 - 1565
  • [10] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
    Gomez, Daniel R.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Hernandez, Mike
    Ye, Rong
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tang, Chad
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    Sepesi, Boris
    William, William N.
    Zhang, Jianjun
    Shi, Qiuling
    Wang, Xin Shelley
    Swisher, Stephen G.
    Heymach, John V.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1672 - 1682